Dabur Clarifies USFDA Observations at Silvassa Plant; No Impact on Operations

Dabur India Limited has issued a clarification regarding media reports on USFDA observations at its Silvassa manufacturing plant (Dadra and Nagar Haveli). The company confirmed that the findings relate to data integrity and maintenance lapses in a small, low-revenue portion of the facility. Key Points: Scope: Observations confined to a minor segment of the Silvassa plant; contributes insignificant revenue to overall operations. Operational Status: Plant remains fully operational; no production halt or product recall initiated. Remediation: Dabur is actively collaborating with USFDA on a Corrective and Preventive Action (CAPA) plan, with regular progress updates being shared. Financial Impact: Company confirms no material impact on financials, operations, or product availability. Governance: Disclosure made under SEBI LODR norms; no other material events requiring disclosure. Strategic Context: Risk Containment: Limiting the scope to a low-revenue segment minimizes business disruption and reputational exposure. Regulatory Engagement: Proactive CAPA submission reflects Dabur's commitment to resolving observations and restoring full compliance standing. Portfolio Resilience: Dabur's diversified manufacturing footprint across India and global markets reduces dependency on any single facility. Outlook: While the USFDA observations represent a near-term regulatory overhang, the limited scope and ongoing remediation mitigate escalation risk. Successful closure of the CAPA process will be critical to restoring the plant's import eligibility for US-bound products. $DABUR